A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy

Inclusion Criteria: * At least one claim for methotrexate or anti-TNF therapy during the study period. First medication received is the index medication, and date of first receipt is the index date * 365 days of continuous pre-index observation immediately prior to the index date * Participants have at least two occurrences of a diagnosis of rheumatoid arthritis within 365 days before and including the index date * No prior use of methotrexate or an anti- tumor necrosis factor (TNF) therapy at any time prior to the index date * Cohort follow-up persists until end of continuous observation or filling the comparator drug